Differential gene expression data of commercial compounds used to assess the performance of human TeraTox assay

The dataset supplements the publication `Optimization of the TeraTox assay for preclinical teratogenicity assessment`.  2022-02-18-TeraTox-commercial-logFC.gct: log2FC matrix of genes by compounds (in concentration ranges) 2022-02-18-TeraTox-commercial-pScore.gct: p-scores (log 10 transformed p-values with the sign of logFC) of genes by compounds 2022-02-18-TeraTox-commercial-featureData.txt: feature annotation in TSV format 2022-02-18-TeraTox-commercial-phenoData.txt: sample annotation in TSV format 2021-06-10-gcGeneFactorAnno-withPositiveCoefs.tsv: gene membership of germ-layer factors, with germ-layer annotation and average expression in copies per million (cpm). Citation: Jaklin, Manuela, Jitao David Zhang, Nicole Schäfer, Nicole Clemann, Paul Barrow, Erich Küng, Lisa Sach-Peltason, Claudia McGinnis, Marcel Leist, and Stefan Kustermann. “Optimization of the TeraTox Assay for Preclinical Teratogenicity Assessment.” Toxicological Sciences 188, no. 1 (July 1, 2022): 17–33. https://doi.org/10.1093/toxsci/kfac046.